Shares of Check Cap Ltd (NASDAQ:CHEK) have been assigned an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.
Analysts have set a 12-month consensus price objective of $10.50 for the company and are anticipating that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 107 out of 256 based on the ratings given to related companies.
Separately, Zacks Investment Research lowered shares of Check Cap from a “buy” rating to a “hold” rating in a research note on Tuesday, April 9th.
Check Cap (NASDAQ:CHEK) last announced its earnings results on Monday, May 13th. The medical research company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. As a group, sell-side analysts expect that Check Cap will post -1.69 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of Check Cap by 96.0% during the 1st quarter. Wells Fargo & Company MN now owns 9,800 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 4,800 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Check Cap by 16.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 40,773 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5,642 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Check Cap during the 1st quarter valued at about $89,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Check Cap by 101.4% during the 1st quarter. Renaissance Technologies LLC now owns 247,442 shares of the medical research company’s stock valued at $668,000 after purchasing an additional 124,600 shares in the last quarter.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Featured Story: What is a Derivative?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.